Search

Your search keyword '"Eleftheriadou, Ioanna"' showing total 362 results
Start Over Author "Eleftheriadou, Ioanna"
362 results on '"Eleftheriadou, Ioanna"'

3. Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma

Author

Gyurdieva, Alexandra, Zajic, Stefan, Chang, Ya-Fang, Houseman, E Andres, Zhong, Shan, Kim, Jaegil, Nathenson, Michael, Faitg, Thomas, Woessner, Mary, Turner, David C, Hasan, Aisha N, Glod, John, Kaplan, Rosandra N, D’Angelo, Sandra P, Araujo, Dejka M, Chow, Warren A, Druta, Mihaela, Demetri, George D, Van Tine, Brian A, Grupp, Stephan A, Fine, Gregg D, and Eleftheriadou, Ioanna

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Clinical Research, Development of treatments and therapeutic interventions, 5.2 Cellular and gene therapies, Antigens, Neoplasm, Biomarkers, CD8-Positive T-Lymphocytes, Humans, Membrane Proteins, Receptors, Antigen, T-Cell, Sarcoma, Synovial, Tumor Microenvironment
Abstract

Autologous T cells transduced to express a high affinity T-cell receptor specific to NY-ESO-1 (letetresgene autoleucel, lete-cel) show promise in the treatment of metastatic synovial sarcoma, with 50% overall response rate. The efficacy of lete-cel treatment in 45 synovial sarcoma patients (NCT01343043) has been previously reported, however, biomarkers predictive of response and resistance remain to be better defined. This post-hoc analysis identifies associations of response to lete-cel with lymphodepleting chemotherapy regimen (LDR), product attributes, cell expansion, cytokines, and tumor gene expression. Responders have higher IL-15 levels pre-infusion (p = 0.011) and receive a higher number of transduced effector memory (CD45RA- CCR7-) CD8 + cells per kg (p = 0.039). Post-infusion, responders have increased IFNγ, IL-6, and peak cell expansion (p

Published
2022

5. Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation

Author

Shah, Viral, Giotopoulos, George, Osaki, Hikari, Meyerhöfer, Markus, Meduri, Eshwar, Gallego-Crespo, Aaron, Behrendt, Malte A., Saura-Pañella, Maria, Tarkar, Aarti, Schubert, Benedict, Yun, Haiyang, Horton, Sarah J., Agrawal-Singh, Shuchi, Haehnel, Patricia S., Basheer, Faisal, Lugo, Dave, Eleftheriadou, Ioanna, Barbash, Olena, Dhar, Arindam, Kühn, Michael W.M., Guezguez, Borhane, Theobald, Matthias, Kindler, Thomas, Gallipoli, Paolo, Yeh, Paul, Dawson, Mark A., Prinjha, Rab K., Huntly, Brian J.P., and Sasca, Daniel

Published
2024
Full Text
View/download PDF

8. l‐Securinine Induces ROS‐Dependent Apoptosis on Pancreatic Cancer Cells via the PI3K/AKT/mTOR Signaling Pathway.

Author

Anastasiou, Ioanna A., Sarantis, Panagiotis, Rebelos, Eleni, Eleftheriadou, Ioanna, Tentolouris, Konstantinos N., Katsaouni, Athanasia, Koustas, Evangelos, Kokala, Vasileia, Karamouzis, Michalis V., and Tentolouris, Nikolaos

Subjects
CELL cycle, REACTIVE oxygen species, WESTERN immunoblotting, PANCREATIC cancer, POLYMERASE chain reaction
Abstract

Accumulating evidence has shown that l‐securinine can, in certain circumstances, suppress tumor development by elevating reactive oxygen species (ROS) levels. The current work set out to examine l‐securinine's apoptotic effects on HuP‐T3 cells as well as any potential underlying molecular mechanism(s) that could explain its action as an anticancer agent. In this study, we used 1.2B4 cells as a control human cell line to verify our findings. Hup‐T3 and 1.2B4 cells were cultured with a medium containing the following dilutions of l‐securinine: 1–10 μΜ for up to 72 h. We examined the viability and proliferation levels of cells in both cell lines. Then, we measured only 1.2B4 insulin levels and content. We also quantified cell apoptosis, cell cycle levels, and the intracellular reactive oxygen species on HuP‐T3 and 1.2B4. Afterwards, we performed a real‐time quantitative polymerase chain reaction and western blot analysis. Our results demonstrated that l‐securinine inhibited both proliferation and growth of Hup‐T3 cells, showing inhibitory and antiproliferative activity in comparison with the control group. In addition, l‐securinine had no impact on the proliferation and growth of 1.2B4 cells, nor on their insulin levels and content. By boosting ROS production, and inhibiting the PI3K/AKT/mTOR signaling pathway, l‐securinine induced apoptosis on HuP‐T3 cells. Pancreatic cancer was successfully inhibited by l‐securinine in vitro. l‐securinine triggers ROS‐dependent apoptosis on pancreatic cancer cells while inhibiting the PI3K/AKT/mTOR signaling pathway. These findings suggest that l‐securinine holds promise as a potential lead for future drug development in the fight against pancreatic adenocarcinoma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. The Association of Vitamin D Receptor Polymorphisms with COVID-19 Severity

Author

Tentolouris, Nikolaos, primary, Achilla, Charoula, additional, Anastasiou, Ioanna A., additional, Eleftheriadou, Ioanna, additional, Tentolouris, Anastasios, additional, Basoulis, Dimitrios, additional, Kosta, Ourania, additional, Lambropoulos, Alexandros, additional, Yavropoulou, Maria P., additional, Chatzikyriakidou, Anthoula, additional, and Jude, Edward B., additional

Published
2024
Full Text
View/download PDF

21. Risk factors for the in‑hospital and 1‑year mortality of elderly patients hospitalized due to COVID‑19‑related pneumonia

Author

Georgakopoulou, Vasiliki, primary, Gkoufa, Aikaterini, additional, Makrodimitri, Sotiria, additional, Tsakanikas, Aristeidis, additional, Basoulis, Dimitrios, additional, Voutsinas, Pantazis, additional, Karamanakos, Georgios, additional, Eliadi, Irene, additional, Samara, Stamatia, additional, Triantafyllou, Maria, additional, Eleftheriadou, Ioanna, additional, Kampouropoulou, Olga, additional, Papageorgiou, Chrysovalantis, additional, Anastasopoulou, Amalia, additional, Papalexis, Petros, additional, Trakas, Ilias, additional, Trakas, Nikolaos, additional, Spandidos, Demetrios, additional, Steiropoulos, Paschalis, additional, and Sipsas, Nikolaos, additional

Published
2023
Full Text
View/download PDF

24. Development of novel targeted lentiviral vectors for gene therapy of motor neuron diseases

Author

Eleftheriadou, Ioanna and Mazarakis, Nicholas

Subjects
610
Abstract

Motor Neuron Diseases (MND) including Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA) are neurodegenerative diseases that can cause progressive paralysis and premature death, while there are no treatments available up to date. Gene therapy using lentiviruses has been successful at alleviating symptoms and extending survival in murine models of both. Restricting transduction to specific cells, is critical for safe and efficient gene therapy. The aim of this study was to generate novel lentiviral vectors with tropism to motor neurons (MNs) using surface engineering, that involves incorporation of a fusogenic glycoprotein (mutated sindbis G) and an antibody recognizing a cell-surface receptor, onto the lentiviral surface. Antibodies against rat Thy1.1, rat p75NTR (Low Affinity Nerve Growth Factor Receptor) and mouse CAR (Coxsackie and adenovirus receptor) receptors expressed on the presynaptic terminal of the neuromuscular junction (NMJ) were cloned and used to surface engineer high titer lentiviral vectors ( Thy1.1, p75NTR and CAR). These vectors preferentially transduced cell lines expressing these receptors and primary motor neuron cultures compared to non-targeted controls. The ability of these vectors to be transported retrogradely and transduce MNs was demonstrated in vitro in compartmented microfluidic cultures in fixed and live imaging experiments. Tropism of these vectors was assessed in vivo in the rat brain following intrastiatal injections. In vivo intramuscular delivery of CAR targeted lentiviral vectors in tibialis anterior of mice lead to transduction of motor neurons in ventral spinal cord. Transduction of spinal cord was further demonstrated by in vivo bioluminescence imaging studies in mice injected intramuscularly with the CAR targeted vectors. This is the first ever demonstration that surface engineering can confer novel trafficking and transduction characteristics to lentiviral vectors. These targeted lentiviral vectors have superior trafficking, transduction and specificity for MNs than previously used lentiviral vectors, making them good candidates for non-invasive CNS -targeted delivery of therapeutics in MN diseases.

Published
2013
Full Text
View/download PDF

26. Improvement of metabolic control after 3-month use of real-time continuous glucose monitoring in patients with type 1 diabetes: a multicenter study in Greece

Author

Eleftheriadou, Ioanna, Didangelos, Triantafyllos, Pappas, Angelos C., Anastasiou, Eleni, Vasilopoulos, Charalampos, Zoupas, Christos, Manes, Christos, Tsatsoulis, Agathocles, Benroubi, Marianna, Pangalos, Emmanuel, Thomakos, Petros, Gerasimidi-Vazeou, Andriani, and Tentolouris, Nikolaos

Published
2019
Full Text
View/download PDF

27. A Pilot Study on the Glucose-Lowering Effects of a Nutritional Supplement in People with Prediabetes

Author

Bemplidakis, Thrasyvoulos, primary, Eleftheriadou, Ioanna, additional, Kosta, Ourania, additional, Tentolouris, Konstantinos, additional, Anastasiou, Ioanna, additional, Agelaki, Christina, additional, Lamprinos, Dimitrios, additional, Papaioannou, Anastasia, additional, Kolovou, Ioanna, additional, Kouka, Vasiliki, additional, Bristianou, Magdalini, additional, Lanaras, Leonidas, additional, and Tentolouris, Nikolaos, additional

Published
2023
Full Text
View/download PDF

33. Treatment with Umbilical Cord Blood Platelet Lysate Gel Improves Healing of Diabetic Foot Ulcer.

Author

Lambadiari, Vaia, Kountouri, Aikaterini, Psahoulia, Fοteini, Koliou, Georgia-Angeliki, Lazaris, Andreas, Michalopoulos, Efstathios, Mallis, Panagiotis, Korakas, Emmanouil, Eleftheriadou, Ioanna, Balampanis, Konstantinos, Sarris, Markos, Tsirigotis, Panagiotis, Geroulakos, George, Stavropoulos-Giokas, Catherine, Dimitriadis, George D., and Tentolouris, Nikolaos

Subjects
CORD blood, DIABETIC foot, BLOOD platelets, HEALING, PLATELET-rich plasma
Abstract

Background: This study was conducted to examine the hypothesis that umbilical cord blood platelet lysate (UCB-PL) gel has a significant impact on the healing rate of DFU. Μethods: In this open-labeled, randomized controlled trial, 110 patients were randomized to treatment with UCB-PL gel (UCB-PL group, n = 52) every three days for one month or dressing with normal saline (control group, n = 58). All participants were followed up for 20 weeks post treatment. Ulcer surface area was assessed with the imitoMeasure application at two, four, and six weeks, and two, four and six months. This study's main outcome was the reduction in ulcer size over the six-month study period. Results: The mean ulcer area at baseline was 4.1 cm2 in the UCB-PL group and 1.7 cm2 in the control group. At six months post treatment, patients on the UCB-PL treatment displayed a significant reduction in ulcer size compared to baseline 0.12 (0–8.16) in contrast to a more modest change in the control group 1.05 (0–24.7). The ulcer area was decreased at the end of the study in 40 patients (97.6%) in the UCB-PL group and 27 (73%) in the control group (Fisher's p = 0.002). Conclusions: The application of UCB-PL gel in DFU resulted in a significant reduction in ulcer size compared to regular saline dressing. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Abstract 6071: Whole-exome RNA sequencing of metastatic synovial sarcomas reveals heterogeneous transcriptomic profile and targetable co-alterations: Cohort study from the French Sarcoma Group

Author

Vanacker, Helene, primary, Brahmi, Mehdi, additional, Meitour, Yannick Le, additional, Bollard, Julien, additional, Attignon, Valery, additional, Meurgey, Alexandra, additional, Jean-Denis, Myriam, additional, Tonon, Laurie, additional, Pokras, Shibani, additional, Klohe, Erika, additional, Nathenson, Michael, additional, Blouch, Kristin, additional, Eleftheriadou, Ioanna, additional, Blay, Jean-Yves, additional, Tirode, Franck, additional, and Dufresne, Armelle, additional

Published
2023
Full Text
View/download PDF

41. 601 Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS)

Author

Kapoor, Gurpreet, primary, Zajic, Stefan, additional, Suchindran, Sunil, additional, Kim, Jaegil, additional, Saxena, Uma, additional, Bhaskar, Aishwarya, additional, Kaczynski, Heather, additional, Nathenson, Michael, additional, D'Souza, Jimson, additional, Rich, Benjamin, additional, D'Angelo, Sandra, additional, Druta, Mihaela, additional, Tine, Brian Van, additional, Somaiah, Neeta, additional, Liebner, David, additional, Schuetze, Scott, additional, and Eleftheriadou, Ioanna, additional

Published
2022
Full Text
View/download PDF

42. Factors predicting poor outcomes of patients treated with tocilizumab for COVID‑19‑associated pneumonia: A retrospective study

Author

Georgakopoulou, Vasiliki, primary, Basoulis, Dimitrios, additional, Voutsinas, Pantazis, additional, Makrodimitri, Sotiria, additional, Samara, Stamatia, additional, Triantafyllou, Maria, additional, Eliadi, Irene, additional, Karamanakos, Georgios, additional, Papageorgiou, Chrysovalantis, additional, Anastasopoulou, Amalia, additional, Bitsani, Aikaterini, additional, Kampouropoulou, Olga, additional, Eleftheriadou, Ioanna, additional, Gkoufa, Aikaterini, additional, Spandidos, Demetrios, additional, Papalexis, Petros, additional, and Sipsas, Nikolaos, additional

Published
2022
Full Text
View/download PDF

45. Preliminary Studies on Optimization of Anti-Parkinson Drug Loaded Lipid Nanoparticles Enriched Hydrogel Formulations for Management of Parkinson’s Disease

Author

Alli Ramesh, A. Mamas Mamas, Kumar Deepak, Alasnag Mirvat, A. Quadros Vanessa, H.L. Purohit Abhishek, Salim Samina, Dey Abhijit, R. S. Santos Adair, Rani Vibha, U. Sneddon Lynne, Pantos Constantinos, Parwani Purvi, Bharti Sushma, A. Anastasiou Ioanna, Yunaiyama Daisuke, Khichar Satyendra, Tentolouris Anastasios, Nagakawa Yuichi, Leopoldo Harada Taiyo, Krishana Bohra Gopal, Mathur Priyanka, Tentolouris Nikolaos, B. Rosemberg Denis, Gorre Thirupathi, Mourouzis Iordanis, Eleftheriadou Ioanna, S. de Abreu Murilo, V. Costa Fabiano, Saito Kazuhiro, V. Kalueff Allan, Yamaguchi Hiroshi, Nagao Toshitaka, V. Rosa Luiz, and Swamy Kumara

Subjects
Drug, business.industry, media_common.quotation_subject, Biomedical Engineering, Medicine (miscellaneous), Medicine, Bioengineering, Pharmacology, business, Management of Parkinson's disease, media_common
Abstract

Introduction: Ropinirole (RP), is a selective dopamine agonist that is used alone or with other medications to treat the symptoms of Parkinson’s disease (PD). RP has low bioavailability of only about 50% due to the first-pass metabolism, and it requires frequent dosing during oral administration. Aim: The objective of the current research was to develop RP-loaded solid lipid nanoparticles (RP- SLNs), nanostructured lipid carriers (RP-NLCs), and their corresponding hydrogels (RP-SLN-C and RP-NLC-C) that could enhance RP therapeutic outcomes during PD treatment. Methods: RP nanoparticles were prepared by homogenization followed by probe sonication and optimized based on particle size, polydispersity index (PDI), zeta potential (ZP), % assay, % entrapment efficiency, and in vitro release studies. Optimized formulations were converted into hydrogel formulations using Carbopol 934 as a gelling polymer and optimized based on rheological and release characteristics. Optimized formulations were further evaluated using differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD), scanning electron microscopy (SEM), freeze-drying, and stability study at refrigerated and room temperatures. Results: The optimized RP-SLN formulation showed particle size and entrapment efficiency of 213.5±3.8 nm and 77.9±3.1% compared to 190.6±3.7 nm and 85.7±1.7% for optimized RP-NLC formulation. PXRD supplemented and confirmed DSC results, RP was entrapped in a molecularly dispersed state inside the core of the lipid nanocarrier. Furthermore, RP-loaded lipid nanocarriers revealed a spherical shape in SEM images. In vitro release studies demonstrated sustained release profiles for RP from SLNs, NLCs, and their hydrogels over 24 h. Optimized SLN, NLC, and nanocarrier- loaded hydrogel formulations were stable over three months at 4ºC and 25ºC storage conditions. Conclusion: Overall, the results demonstrated that lipid nanocarriers and their corresponding hydrogel formulations can be considered as a topical drug delivery vehicle for RP during the treatment of PD.

Published
2021
Full Text
View/download PDF

49. Low concentrations of bisphenol A promote the activation of the mitochondrial apoptotic pathway on Beta‐TC‐6 cells via the generation of intracellular reactive oxygen species and mitochondrial superoxide

Author

Anastasiou, Ioanna A., primary, Eleftheriadou, Ioanna, additional, Tentolouris, Anastasios, additional, Sarantis, Panagiotis, additional, Angelopoulou, Andriani, additional, Katsaouni, Athanasia, additional, Mourouzis, Iordanis, additional, Karamouzis, Michalis V., additional, Gorgoulis, Vasilios, additional, Pantos, Constantinos, additional, and Tentolouris, Nikolaos, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results